Anmelden Kostenlos registrieren

Theratechnologies Schwankungsanfälligkeit

Was ist das Schwankungsanfälligkeit von Theratechnologies?

Schwankungsanfälligkeit von Theratechnologies Inc. ist 4.91%

Was ist die Definition von Schwankungsanfälligkeit?

Die Schwankungsanfälligkeit oder Prozent des durchschnittlichen wahren Bereichs (ATRP 14) ist die ATR, ausgedrückt als Prozentsatz des Schlusskurses.

Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.

The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.

Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets

Schwankungsanfälligkeit von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Theratechnologies

Was macht Theratechnologies?

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.

Unternehmen mit schwankungsanfälligkeit ähnlich Theratechnologies